Clinical Trials

Triple Negative Breast Neoplasms

NCT02876107 2026-04-15

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

42 enrolled

Breast Neoplasms, Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06545331 2026-04-15

DELTA-101

BreastGastrointestinalThoracic

396 enrolled

Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT07045311 2026-04-15

JS207 Combination Therapy in Triple-negative Breast Cancer

80 enrolled

Triple Negative Breast Neoplasms

NCT04677816 2026-04-14

Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients

50 enrolled

Vitamin D Deficiency, Triple Negative Breast Neoplasms

NCT05377996 2026-04-14

A Study of XMT-1660 in Participants With Solid Tumors

319 enrolled

BreastGynecologic

Breast Neoplasms, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07311993 2026-04-14

Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

60 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07528768 2026-04-14

Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer

750 enrolled

Phase 1/2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT02802423 2026-04-13

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.

44 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02883062 2026-04-13

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

67 enrolled 16 charts

Phase 3 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02954874 2026-04-13

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

1,155 enrolled

Phase 1 Active not recruiting

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04052555 2026-04-13

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

42 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04225117 2026-04-13

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

BreastGastrointestinalHead & NeckThoracic

329 enrolled 23 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT04345913 2026-04-13

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

Phase 1/2 Active not recruiting

24 enrolled 24 charts

Phase 1 Active not recruiting

Triple Negative Breast Neoplasms

NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

74 enrolled

BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

NCT04768426 2026-04-13

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

40 enrolled

BreastDermatologicGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04895709 2026-04-13

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

949 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT05005403 2026-04-13

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

BreastGastrointestinalHead & NeckThoracic

694 enrolled

Anophthalmia with pulmonary hypoplasia, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05111561 2026-04-13

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

Phase 1 Suspended

42 enrolled

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05422794 2026-04-13

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

57 enrolled

Triple Negative Breast Neoplasms

NCT05673200 2026-04-13

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

32 enrolled

Phase 1 Active not recruiting

Triple Negative Breast Neoplasms

NCT06238479 2026-04-13

EXCEED

490 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Ureteral Neoplasms, Urologic Neoplasms, Triple Negative Breast Neoplasms

NCT06393374 2026-04-13

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Phase 3 Recruiting

1,530 enrolled

Triple Negative Breast Neoplasms

NCT06841354 2026-04-13

TroFuse-011

Phase 3 Recruiting

1,000 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT07069595 2026-04-13

PREDICT-RD

78 enrolled

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07137416 2026-04-13

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

36 enrolled

Phase 1 Not yet recruiting

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07297667 2026-04-13

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

30 enrolled

BreastGenitourinarySarcoma

Carcinoma, Renal Cell, Sarcoma, Alveolar Soft Part, Triple Negative Breast Neoplasms

NCT07340541 2026-04-13

EVOLVE-BDT

700 enrolled

BreastCNSGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07523529 2026-04-13

SELECT-2CAR

Phase 1/2 Recruiting

72 enrolled

Glioblastoma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT07525869 2026-04-13

An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy

Phase NA Recruiting

40 enrolled

Phase NA Not yet recruiting

Triple Negative Breast Neoplasms

NCT07513311 2026-04-09

RESTORE

75 enrolled

Triple Negative Breast Neoplasms

NCT02595905 2026-04-08

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

Phase 2 Completed

344 enrolled 11 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06562192 2026-04-08

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

BreastGastrointestinalThoracic

162 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT06649331 2026-04-08

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

160 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07517198 2026-04-08

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

40 enrolled

Margins of Excision, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Liver Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05579366 2026-04-07

RAINFOL-01

Phase 1/2 Recruiting

764 enrolled

BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06604858 2026-04-07

TELESCOPE

31 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07078604 2026-04-07

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

20 enrolled